Autologous Platelet-Rich Plasma (PRP) is named as an intervention in 2 current clinical trials in our France and South Korea registers. None are recruiting at the moment. The most common phase is Not applicable. The sponsor with the most trials is Hospices Civils de Lyon (1). The most-studied condition is Olfactory Dysfunction.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
The Analysis of Efficacy Factors for Autologous Platelet-Rich Plasma Therapy in the Treatment of Elbow Tendinopathy
NCT06815042 · ClinicalTrials.gov ↗ · Elbow Tendinopathy
|
Phase 4 | Not yet open | CHA University | South Korea |
|
PANDORA: Evaluation of Platelet-rich Plasma in Non-tumoural Odour Disorders: a Descriptive Pilot Study.
NCT07473830 · ClinicalTrials.gov ↗ · Olfactory Dysfunction, Post-traumatic Olfactory Dysfunction, Age-related Degenerative Olfactory Dysfunction
|
Not applicable | Not yet open | Hospices Civils de Lyon | France |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Hospices Civils de Lyon | 1 |
| CHA University | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in France | 1 | 0 |
| Clinical trials in South Korea | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our France and South Korea registers name Autologous Platelet-Rich Plasma (PRP) as a drug or biological intervention, as of the registry sync on 28 September 2026. Completed and withdrawn studies are not counted.
Not at the moment. None of the 2 trials in our registers is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
Hospices Civils de Lyon (1) and CHA University (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Autologous Platelet-Rich Plasma (PRP) works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Autologous Platelet-Rich Plasma (PRP) works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Autologous Platelet-Rich Plasma (PRP) (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 28 Sep 2026.